What is Morphogenesis?
Morphogenesis, operating within the biotechnology sector, is dedicated to advancing innovative therapies that modulate the immune system. Their core focus lies in proprietary IMMUNE FX (IFX) technologies and the development of bi-specific immune modulating antibody drug conjugates (ADCs). The company is actively engaged in clinical studies, advancing a pipeline that includes promising candidates such as IFx-2.0 and IFx-3.0. Morphogenesis targets investors and stakeholders keen on breakthroughs in immunology and personalized medicine, aiming to enhance patient outcomes through rigorous scientific research and development. Based in Tampa, Florida, the company's strategic direction is geared towards translating cutting-edge research into tangible therapeutic solutions.
How much funding has Morphogenesis raised?
Morphogenesis has raised a total of $22.1M across 5 funding rounds:
Private Equity
$2.7M
Series A
$16M
Debt
$350K
Other Financing Round
$2.7M
Debt
$294K
Private Equity (2017): $2.7M, investors not publicly disclosed
Series A (2018): $16M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Other Financing Round (2020): $2.7M, investors not publicly disclosed
Debt (2021): $294K backed by PPP
Key Investors in Morphogenesis
PPP
Public-Private Partnership
What's next for Morphogenesis?
With the recent influx of major strategic investment, Morphogenesis is well-positioned to accelerate its research and development initiatives, particularly in advancing its IMMUNE FX technologies and antibody drug conjugate pipeline. The company's focus on clinical studies suggests a near-term emphasis on progressing its lead candidates, IFx-2.0 and IFx-3.0, through regulatory pathways. This enterprise-level backing is likely to fuel expansion of its scientific team, enhance manufacturing capabilities, and potentially support strategic partnerships or acquisitions to broaden its therapeutic reach. Morphogenesis's commitment to personalized medicine and immunology indicates a strategic intent to capture a significant share of a rapidly growing market.
See full Morphogenesis company page
